NCT02610777已完成2 期
A Phase 2, Randomized, Controlled, Open-Label, Clinical Study of the Efficacy and Safety of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Low-Blast Acute Myelogenous Leukemia
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 120
- 试验地点
- 59
- 主要终点
- Overall Survival (OS)
研究概览
简要总结
The purpose of this study is to evaluate the efficacy and safety of pevonedistat plus azacitidine versus single-agent azacitidine in participants with HR-MDS or CMML, or low-blast AML.
详细描述
The drug being tested in this study is called pevonedistat. Pevonedistat is being tested to treat people with MDS or CMML, or low-blast AML as a combination treatment with azacitidine. This study will look at the overall survival, event free survival and response to treatment in people who take pevonedistat and azacitidine when compared to people who take single-agent azacitidine.
The study will enroll 120 participants. Once enrolled, participants will be randomly assigned (by chance, like flipping a coin) to one of the two treatment groups in 28-day treatment cycles:
- Pevonedistat 20 mg/m^2 and azacitidine 75 mg/m^2 combination
- Single-agent azacitidine 75 mg/m^2
All participants will receive azacitidine via intravenous or subcutaneous route. Participants randomized to the combination arm will also receive pevonedistat intravenous infusion.
This multi-center trial will be conducted worldwide. The overall time to participate in this study is approximately 44 months. Participants will attend the end-of-treatment visit 30 days after the last dose of study drug or before the start of subsequent anti-neoplastic therapy if that occurs sooner. Participants will enter event-free survival follow-up or response follow-up (study visits every 3 months) if their disease has not transformed to AML (for participants with HR MDS or CMML) or progressed (for participants with low-blast AML), and they have not started subsequent therapy. Participants will also enter overall survival follow-up (contacted every 3 months to document subsequent therapies and survival status).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female participants 18 years or older.
- •Morphologically confirmed diagnosis of MDS or nonproliferative CMML (that is, with white blood cells [WBC] <20,000 per microliter [/mcL]) or low blast AML based on 1 of the following:
- •French American British (FAB) Classifications:
- •Refractory anemia with excess blasts (RAEB) - defined as having 5% to 20% myeloblasts in the bone marrow.
- •CMML with 10% to 19% myeloblasts in the bone marrow and/or 5% to 19% blasts in the blood.
- •WHO Classifications:
- •RAEB 1 - defined as having 5% to 9% myeloblasts in the bone marrow.
- •RAEB 2 - defined as having 10% to 19% myeloblasts in the bone marrow and/or 5% to 19% blasts in the blood.
- •CMML 2 - defined as having 10% to 19% myeloblasts in the bone marrow and/or 5% to 19% blasts in the blood.
- •CMML 1 (Although CMML 1 is defined as having <10% myeloblasts in the bone marrow and/or <5% blasts in the blood, these participants may enroll only if bone marrow blasts >=5%.
- •WHO defined AML with 20% to 30% myeloblasts in the bone marrow and <30% myeloblasts in peripheral blood who are deemed by the investigator to be appropriate for azacitidine based therapy.
- •For MDS and CMML participants, prognostic risk category, based on the Revised International Prognostic Scoring System (IPSS R), of:
- •Very high (>6 points),
- •High (>4.5 to 6 points), or
- •Intermediate (>3 to 4.5 points): a participant determined to be in the Intermediate Prognostic Risk Category is only allowable in the setting of >=5% bone marrow myeloblasts.
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0 to
- •Clinical laboratory values within the following parameters (repeat within 3 days before the first dose of study drug if laboratory values used for randomization were obtained more than 3 days before the first dose of study drug):
- •Albumin >2.7 g/dL.
- •Total bilirubin <upper limit of normal (ULN) except in participants with Gilbert's syndrome. Participants with Gilbert's syndrome may enroll if direct bilirubin <=1.5*ULN of the direct bilirubin.
- •Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) <2.5*ULN.
- •Creatinine clearance >=50 milliliter per minutes (mL/min).
- •Hb >8 g/dL. Participants may be transfused to achieve this value. Elevated indirect bilirubin due to post transfusion hemolysis is allowed.
- •For CMML participants: WBC count <20,000/mcL before administration of the first dose of study drug on Cycle 1 Day 1; participants must have been off hydroxyurea for at least 1 week prior to WBC count assessment.
- •Ability to undergo the study required bone marrow sample collection procedures.
- •Suitable venous access for the study required blood sampling (that is, including pharmacokinetic (PK) and biomarker sampling).
- •Female participants who:
- •Are postmenopausal for at least 1 year before the Screening visit , or
- •Are surgically sterile, or
- •If they are of childbearing potential, agree to practice 1 highly effective method and 1 additional effective (barrier) method of contraception at the same time, from the time of signing the informed consent through 4 months after the last dose of study drug, or
- •Agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the participant. (Periodic abstinence [example, calendar, ovulation, symptothermal, postovulation methods] withdrawal, spermicides only, and lactational amenorrhea are not acceptable methods of contraception. Female and male condoms should not be used together).
- •Male participants, even if surgically sterilized (that is, status postvasectomy), who:
- •Agree to practice effective barrier contraception during the entire study treatment period and through 4 months after the last dose of study drug, or
- •Agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the participant. (Periodic abstinence [example, calendar, ovulation, symptothermal, postovulation methods for the female partner] withdrawal, spermicides only, and lactational amenorrhea are not acceptable methods of contraception. Female and male condoms should not be used together).
- •Voluntary written consent must be given before performance of any study related procedure not part of standard medical care, with the understanding that consent may be withdrawn by the participant at any time without prejudice to future medical care.
排除标准
- •Previous treatment with decitabine or azacitidine or other hypomethylating agent.
- •Acute promyelocytic leukemia as diagnosed by morphologic examination of bone marrow, by fluorescent in situ hybridization or cytogenetics of peripheral blood or bone marrow, or by other accepted analysis.
- •Eligible for allogenic stem cell transplantation.
- •Participants with MDS, CMML, or low blast AML, whose only site of disease is extramedullary, example, the skin.
- •Any serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of study procedures or could limit participant expected survival to less than 6 months.
- •Treatment with any anti leukemic/anti MDS therapies (example, lenalidomide, cytarabine, anthracyclines, purine analogs) or with any investigational products within 14 days before the first dose of any study drug.
- •Known hypersensitivity to mannitol.
- •Active uncontrolled infection or severe infectious disease, such as severe pneumonia, meningitis, or septicemia.
- •Major surgery within 14 days before first dose or a scheduled surgery during study period; insertion of a venous access device (example, catheter, port) is not considered major surgery.
- •Diagnosed or treated for another malignancy within 2 years before randomization or previously diagnosed with another malignancy and have any evidence of residual disease. Participants with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone resection.
- •Life threatening illness unrelated to cancer.
- •Prothrombin time (PT) or prolongation of the activated thromboplastin time (aPTT) >1.5 ULN or active uncontrolled coagulopathy or bleeding disorder.
- •Known human immunodeficiency virus (HIV) seropositive.
- •Known hepatitis B surface antigen seropositive, or known or suspected active hepatitis C infection. Note: Participants who have isolated positive hepatitis B core antibody (that is, in the setting of negative hepatitis B surface antigen and negative hepatitis B surface antibody) must have an undetectable hepatitis B viral load.
- •Known hepatic cirrhosis or severe pre-existing hepatic impairment.
- •Known cardiopulmonary disease defined as unstable angina, clinically significant arrhythmia, congestive heart failure (New York Heart Association [NYHA] Class III or IV) and/or myocardial infarction within 6 months prior to first dose, or severe pulmonary hypertension. As an example, well controlled atrial fibrillation would not be an exclusion whereas uncontrolled atrial fibrillation would be an exclusion.
- •Treatment with strong cytochrome P450 (CYP) 3A inhibitors or inducers within 14 days before the first dose of study drug.
- •Systemic antineoplastic therapy or radiotherapy for other malignant conditions within 12 months before the first dose of any study drug, except for hydroxyurea.
- •Female participants who are lactating and breast feeding or have a positive serum pregnancy test during the Screening period or a positive urine pregnancy test on Day 1 before first dose of study drug.
- •Female participants who intend to donate eggs (ova) during the course of this study or 4 months after receiving their last dose of study drug(s).
- •Male participants who intend to donate sperm during the course of this study or 4 months after receiving their last dose of study drug(s).
研究组 & 干预措施
Azacitidine 75 mg/m^2
Active Comparator
Azacitidine 75 mg/m^2, infusion, intravenously or subcutaneously, on Day 1 through Day 5, Days 8 and 9 in 28-day treatment cycles until unacceptable toxicity, relapse, transformation to AML (for participants with HR MDS or CMML), or progressive disease (for participants with low-blast AML).
干预措施: Azacitidine (Drug)
Azacitidine 75 mg/m^2 + Pevonedistat 20 mg/m^2
Experimental
Azacitidine 75 mg/m^2, infusion, intravenously or subcutaneously, on Day 1 through Day 5, Days 8 and 9 and pevonedistat 20 mg/m^2, infusion, intravenously, on Days 1, 3, and 5 in 28-day treatment cycles until unacceptable toxicity, relapse, transformation to AML (for participants with HR MDS or CMML), or progressive disease (for participants with low-blast AML).
干预措施: Azacitidine (Drug)
Azacitidine 75 mg/m^2 + Pevonedistat 20 mg/m^2
Experimental
Azacitidine 75 mg/m^2, infusion, intravenously or subcutaneously, on Day 1 through Day 5, Days 8 and 9 and pevonedistat 20 mg/m^2, infusion, intravenously, on Days 1, 3, and 5 in 28-day treatment cycles until unacceptable toxicity, relapse, transformation to AML (for participants with HR MDS or CMML), or progressive disease (for participants with low-blast AML).
干预措施: Pevonedistat (Drug)
结局指标
主要结局
Overall Survival (OS)
时间窗: From date of randomization until death (up to 3 years and 5 months)
OS was defined as the time from the date of randomization to the date of death due to any cause. Participants without documented death at the time of the analysis were censored at the date the participant was last known to be alive. The Kaplan Meier estimates was used for the analysis.
次要结局
- Percentage of Participants With CR in Low-blast AML by Cycle 4(From the date of randomization until CR by Cycle 4 (cycle length=28 days))
- Event-Free Survival (EFS)(From date of randomization until transformation to AML, or death due to any cause (up to approximately 5 years))
- Six-month Survival Rate(Month 6)
- Time to AML Transformation in HR MDS or CMML Participants(From date of randomization until transformation to AML (up to approximately 5 years))
- Percentage of Participants With CR and PR by Cycle 4(From date of randomization until CR and PR, by Cycle 4 (cycle length=28 days))
- One-year Survival Rate(Month 12)
- Percentage of Participants With Complete Remission (CR)(From date of randomization until CR (up to approximately 5 years))
- Percentage of Participants With Overall Response(From date of randomization until CR, PR, or hematologic improvement (HI) (up to approximately 5 years))
- Percentage of Participants With CR in Low-blast AML(From date of randomization until CR (up to approximately 5 years))
- Duration of Overall Response(From date of randomization until CR, PR or HI (up to approximately 5 years))
- Number of Participants in the Safety Analysis Population With Clinically Significant Change From Baseline Values in Vital Signs Reported as TEAEs(From date of first dose up to 30 days after administration of the last dose of any study drug (up to approximately 5 years))
- Percentage of Participants With CR and Partial Remission (PR)(From date of randomization until CR and PR (up to approximately 5 years))
- Time to Subsequent Therapy(From date of randomization up to approximately 5 years)
- Percentage of Participants With at Least 1 Inpatient Hospital Admissions Related to HR MDS, CMML or Low-blast AML(From date of randomization until transformation to AML or until initiation of subsequent therapy (up to approximately 5 years))
- Time to Progressive Disease (PD), Relapse, or Death(From date of randomization until PD, relapse or death (up to approximately 5 years))
- Number of Participants Reporting One or More Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)(From date of first dose up to 30 days after administration of the last dose of any study drug (up to approximately 5 years))
- Percentage of Participants With CR by Cycle 4(From date of randomization until CR by Cycle 4 (cycle length is equal to [=] 28 days))
- Percentage of Participants With Overall Response by Cycle 4(From date of randomization until CR, PR or HI, by Cycle 4 (cycle length=28 days))
- Duration of Complete Remission (CR) in Low-blast AML(From date of randomization until CR (up to approximately 5 years))
- Time to First CR or PR(From date of randomization until CR or PR (up to approximately 5 years))
- Duration of Complete Remission (CR)(From date of randomization until CR (up to approximately 5 years))
- Percentage of Participants With Red Blood Cells (RBCs) and Platelet-transfusion Independence(8 weeks before randomization through 30 days after last dose of any study drug (up to approximately 5 years and 3 months))
- Number of Participants in the Safety Analysis Population With Clinically Significant Laboratory Abnormalities Reported as TEAEs(From date of first dose up to 30 days after administration of the last dose of any study drug (up to approximately 5 years))
- Number of Participants With Change From Baseline Values in Eastern Cooperative Oncology Group (ECOG) Performance Status(From date of first dose up to 30 days after administration of the last dose of any study drug (up to approximately 5 years))
- Number of Participants in the Safety Analysis Population With Clinically Significant Change From Baseline in Electrocardiogram (ECG) Values Reported as TEAEs(From date of first dose up to 30 days after administration of the last dose of any study drug (up to approximately 5 years))
- Duration of Complete Remission (CR) and Partial Remission (PR)(From date of randomization until CR or PR (up to approximately 5 years))
研究者
研究点 (59)
Loading locations...
相似试验
已完成
3 期
Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)Leukemia, Myelomonocytic, ChronicLeukemia, Myeloid, AcuteMyelodysplastic SyndromeNCT03268954Takeda454
已完成
2 期
Pevonedistat and Azacitidine in MDS or MDS/MPN Patients Who Fail Primary Therapy With DNA Methyl Transferase InhibitorsMyelodysplastic SyndromesMyeloproliferative NeoplasmNCT03238248Vanderbilt-Ingram Cancer Center71
已完成
2 期
A Study of Pevonedistat and Venetoclax Combined With Azacitidine to Treat Acute Myeloid Leukemia (AML) in Adults Unable to Receive Intensive ChemotherapyAcute Myeloid Leukemia (AML)NCT04266795Takeda164
已完成
1 期
A Study of Pevonedistat in Adult East Asian ParticipantsJPRN-jRCT2080223194Takeda Pharmaceutical Company Limited23
撤回
2 期
Pevonedistat With Azacitidine Versus Azacitidine Alone in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaRecurrent Acute Myeloid LeukemiaRefractory Acute Myeloid LeukemiaNCT03745352National Cancer Institute (NCI)